esg performance summary report report trust one three longterm priorities commitments essential achieve purpose data summary drive longterm growth add value society sasb index united nations global compact shareholders communication progress global reporting initiative commitments support reporting guidelines trust priority drive progress document provides comprehensive assurance report key areas make significant summary environmental social public policies available online impact ensure running governance esg data across business responsible way business complements wider reporting responsible business commitments seek address annual report report progress annual report material topics relevant trust commitments stakeholder engagement stakeholders business responsible business pages gskcom progress trust commitments designed help us respond climate change resilience tcfd challenges opportunities within industry society broadly online reporting contribute many un materiality assessment sustainable development goals human rights scienceled global healthcare sustainable development goals company biggest contribution political advocacy towards goal ensure healthy lives patient group funding promote wellbeing ages trade association memberships charitable grant contributions cautionary statement criteria working public policy groups see document cautionary statement regarding forwardlooking statements modern slavery act statement march commitments commitments detailed support trust priority drive progress key areas make significant impact ensure running business responsible way report progress gsk annual report using science making modern technology products affordable employer address health needs available new medical innovations pricing engaged people develop differentiated highquality needed medicines improve health millions people year making achieve maintain competitive employee engagement vaccines consumer healthcare products improve products available responsible prices score health sustainable business inclusion diversity global health product reach accelerate progress inclusion diversity including improve global health impact rd infectious use access strategies reach million undeserved aspirational targets female ethnically diverse diseases affect children young people developing people developing countries products representation senior roles end recognition disability confident employer lgbt indices countries focusing hiv malaria tb healthcare access health security partner improve disease prevention awareness health wellbeing development help world better prepare future disease outbreaks access healthcare services million people leading company support employee health wellbeing personal development pandemic potential tackle antimicrobial resistance responsible business reliable supply ethics values data engagement environment commit quality safety reliable supply operate ethical valuesdriven culture use data responsibly transparently net zero impact climate net products patients consumers issues responded swiftly improve patient scientific engagement positive impact nature transparently gsk esg performance summary march data summary notes general company information employees us europe international total employees fte financials total operating profit pharmaceutical business revenue vaccines business revenue consumer business revenue total revenue community cash million investment totals product inkind million time million management costs million total access affordability doses synflorix vaccine supplied gavi million doses rotarix vaccine supplied gavi million albendazole tablets donated help eliminate lymphatic filariasis millions albendazole tablets donated help treat intestinal worms millions value gsk medicine vaccines prescribed us patient assistance programme cogs million usd year change list net price change combined average net price pharmaceutical vaccines portfolio us since previous year change average list price us since previous year year list net price cagr compounded growth rate change net price discounts rebates allowances products us past years change average list price us past years new methodology fully account administrative costs bridge access benlystanucala patient assistance programs led significant increase management costs ass drug administration programmes disruptedpaused due covid pandemic leading reduced donation numbers c alculated across gsk viiv healthcare products gsk esg performance summary march data summary continued total notes access affordability continued product reach target people access generic dolutegravir product voluntary chronic ongoing treatment include cumulative total number licensing agreements million access rather annual data baseline estimated children reached synflorix gavi ' based doses per course estimates wastage estimated children reached rotarix gavi ' based doses per course estimates wastage estimated girls reached cervarix gavi ' based doses per course estimates wastage estimated people reached oral polio vaccine opv ' based recommended doses polioendemic countries estimates wastage people reached us patient assistance programme ' people reached products access strategies health access target people accessing healthcare service worker educational session million work save children ' baseline people accessing malaria services comic relief partnership ' healthcare workers trained partners ' people accessing healthcare worker service facility result health worker training programmes ' people reached viiv healthcare 's positive action children fund pacf grants children accessing treatmentcare cleft conditions smile train partnership ' hcpspharmacists trained partners se asia india dengue programme paused due fever programmes ' agreement ngo partner shift focus covid relief efforts people accessing dengue fever services partners india programme paused due agreement ngo partner shift focus covid relief efforts people reached programmes improve disease prevention awareness access healthcare services gavi may distribute different times within year provided many doses potential reach stated number people data driven combination routine programme multiage cohorts part hpv demonstration projects data estimated based previous reach partner programmes level funding final data available april captures figures frontline health worker training programme well new ceo roundtable collaboration gsk esg performance summary march data summary continued notes people engagement employee survey engagement score employee survey response rate gender diversity percentage women employees svpvp level director level manager level total women management percentage women board percentage females stemrelated positions health safety number fatalities employees complementary workers assured dnv gsk direct supervision fatalities contractors gsk direct supervision reportable incidents lost time assured dnv lost time reportable injury illness rate per hours worked assured dnv reportable incidents without lost time assured dnv reportable injury illness rate per hours worked assured dnv hours worked million talent leadership number graduates recruited future leaders programme development number postgraduates recruited esprit programme number apprentices recruited gsk esg performance summary march data summary continued notes people continued employee turnover overall turnover calculated number permanent employees left gsk reason divided average permanent headcount turnover voluntary leavers calculated number permanent employees voluntarily left gsk divided average permanent headcount gender split permanent leavers calculated number permanent employees left gsk reason within period male female male female divided total number permanent leavers left reason within period overall turnover male overall turnover female hiring total number new hires open positions filled internal candidates internal hires workforce breakdown years old age including years old permanent temporary employees years old gsk esg performance summary march data summary continued svpvp director manager employees people continued ethnic diversity us ethnically diverse total american indian alaska native asian black african american hispanic latinx native hawaiian pacific islander two races white total ethnic diversity uk ethnically diverse total asian black mixed white total data represents responded identify race ethnicity category us employees actively respond identify race ethnicity category indicated prefer say uk actively respond indicated prefer say first year reporting ethnicity data comparable historic data start report next report insufficient data report fewer employees gsk esg performance summary march data summary continued notes environment energy natural gas gwh coal gwh electricity used gwh electricity purchased gwh steam hot water gwh fuels gwh energy biomass gwh onsite generated renewable electricity gwh purchased renewable electricity gwh assured dnv renewable electricityused electricity total energy gwh assured dnv carbon scope onsite fuel use thousands tonnes co e emissions sales force vehicles thousands tonnes co e propellant emissions manufacture inhalers thousands tonnes co e onsite waste waste water treatment thousands tonnes co e refrigerant gas losses thousands tonnes co e total scope emissions thousands tonnes co e assured dnv electricity marketbased emissions thousands tonnes co e steamhot water thousands tonnes co e compressed air thousands tonnes co e chilled water thousands tonnes co e total scope emissions marketbased thousands tonnes co e assured dnv scope locationbased emissions thousand tonnes co e assured dnv total scope emissions marketbased thousands tonnes co e assured dnv fermentationbiogenic releases thousands tonnes co e gsk esg performance summary march data summary continued notes environment continued carbon scope purchased goods services thousands tonnes co e emissions capital goods thousands tonnes co e fuel energy related activities thousands tonnes co e transportation distribution upstream thousands tonnes co e waste generated operations thousands tonnes co e business travel thousands tonnes co e employee commuting thousands tonnes co e leased assets upstream thousands tonnes co e transportation distribution downstream thousands tonnes co e processing sold products thousands tonnes co e use sold products thousands tonnes co e e missions use propellant based inhalers patients assured dnv thousands tonnes co e end life thousands tonnes co e leased assets downstream thousands tonnes co e franchises thousands tonnes co e investments thousands tonnes co e total scope emissions thousands tonnes co e ozone depleting odp investory cfc hcfc equipment kg cfce substances odp calculated releases cfc equiv kg cfce water use municipal million ground water million tankers million total water use million assured dnv recycled sources million water use high water risk sites million assured dnv propellant emissions data collected internal systems accurate picture scope ghg emissions later year e missions classified downstream transportation previous years reclassified upstream transportation emissions advice carbon trust ee x gsks high water risk sites gsk esg performance summary march data summary continued notes environment continued water discharge wastewater municipal sewer million wastewater surface water million wastewater million wastewater discharged land million wastewater recharged aquifer rainwater million wastewater recharged aquifer treated effluent million total wastewater discharged million assured dnv waste beneficial use hazardous waste thousand tonnes beneficial use nonhazardous waste thousand tonnes total beneficial use waste thousand tonnes assured dnv nonbeneficial use hazardous waste thousand tonnes nonbeneficial use nonhazardous waste thousand tonnes total nonbeneficial use waste thousand tonnes assured dnv total overall waste thousand tonnes assured dnv hazardous waste landfill thousand tonnes nonhazardous waste landfill thousand tonnes total waste landfill thousand tonnes assured dnv percentage waste sent beneficial use compliance ehs internal audits gsk sites facilities ehs ethics labour rights audits rd party suppliers environmental fines environmental spend million remediation take responsibility removing pollution contaminants soil surface ground water facilities used previously disposal sites waste management companies used gsk esg performance summary march data summary continued notes ethical conduct compliance percentage employees agreed work environment encouraged ethical behaviour even face pressures meet business objectives employees disciplined policy violations breakdown types policy violation behaviour workplace mandatory training completion good manufacturing distribution practices marketing promotional activities expenses employees dismissed agreed leave company voluntarily documented warnings political engagement spend federal lobbying activities data registered us federal lobbying register includes cost operating office washington dc cost travel consulting cost representing interests eu institutions data published eu transparency register political action committee contributions us employees state federal breakdown pac spend available online candidates clinical trial transparency clinical trial data publicly available trial result summaries cumulative studies clinical study reports posted register trials listed patient level data available request research teams approved access gsk trial data n changed way collect disciplinary data improve clarity example removing number categories deem behavioural policy violation sanctions result absence work due illness reduced number reflects changes individual employees subject multiple allegations resulting disciplinary action policy violation types fit categories specified includes latest available figures previous year figures reporting year published april publication document new methodology introduced gsk esg performance summary march data summary continued notes product safety quality quality safety audits rd parties quality processes audits clinical trial audits trials conducted rd parties behalf ensuring quality regulatory inspections pharmaceutical business manufacturing regulatory inspections vaccines business supply regulatory inspections consumer healthcare business total product recalls number fda product pharmaceuticals nr nr recalls business vaccines nr nr class iiiiii consumer healthcare nr nr number fda pharmaceuticals nr nr enforcement actions vaccines nr nr taken response consumer healthcare nr nr violations current good manufacturing practices cgmp c lass iii recall represents total consumer healthcare products produced globally comprises class ii recalls class iii representing total consumer healthcare product batches manufactured gsk esg performance summary march environmental data terminology kpi definition method reporting boundary published environmental data covers facilities owned leased gsk gsk publish data aligned calendar year however joint venture partners gsk full operational control except december values include estimates based december small commercial offices distribution centres required report values actual data available time publication data environmental impacts unless one following criteria met restated correct december estimates reporting period total energy usage mwh per annum baseline year environmental targets total water per annum environmental data sites joined gsk network part total waste generated tonnes per annum gskpfizer consumer healthcare jv integrated gsk data ensures gsk reporting environmental impacts energy includes purchased energy grid electricity natural gas coal energy data based invoice data utility companies diesel fuels renewably generated energy solar wind meter readings biomass purchased renewable electricity allocated site evidence purchased renewable electricity renewable electricity generated supplier supply contract place retirements certificates origin purchased supply agreement includes evidence origin may occur reporting period rec regos part power purchase agreement ppa water includes water supplied withdrawn gsk water data based invoice data suppliers meter readings sites captured rainwater recycled water measured reported included total water used calculation high water risk includes water supplied sites identified gsk high water risk gsk mapped geographic location sites outputs site assessment tools wri aqueduct wwfdeg water risk filter identify sites regions highwater stress gsk originally identified high risk water sites due network changes currently seven high risk water sites network detailed water stewardship risk assessment covering local water availability water quality local regulatory framework cape town south africa access water sanitation performed classify boudouaou algeria whether site determined gsk high water risk site jamshoro pakistan karachi f pakistan following review site xochimilco mexico karachi west wharf pakistan removed site jamshoro pakistan added list nashik india high water risk sites data restated reflect oak hill usa change gsk yet completed water stewardship risk assessments sites joined network part pfizer consumer healthcare jv waste water includes wastewater sent municipal sewer discharged surface wastewater data based invoice data utility companies water treatment site waste water used irrigation wastewater used meter readings calculation based water use absence recharge aquifers accordance local regulations meter liquid waste waste solvents contain water reported separately wastes gsk esg performance summary march environmental data terminology continued kpi definition method scope carbon emissions gsk scope emissions cover emissions direct combustion fuels carbon emissions calculated co equivalent per ghg sites generate heat electricity emissions sales force protocol corporate accounting reporting standard vehicles fugitive losses propellant manufacturing inhalers carbon emission factors calorific factors combustion losses refrigerants used gsk owned ancillary equipment natural gas diesel coal fuels taken uk onsite waste waste water treatment government emission conversion factors greenhouse gas company reporting edition carbon emissions sales force travel calculated based distance travelled directly fuel use added estimate approx offices distance driven data available carbon emissions refrigerant losses based quantities refrigerant used top equipment biogenic emissions reported separately included scope total emissions scope carbon emissions gsk scope emissions include purchased electricity steam compressed carbon emission factors purchased electricity taken air chilled water international energy agency statistics co fuel combustion edition gsk use marketbased scope emissions reporting purposes carbon emission factors purchased heat steam chilled water taken uk government emission conversion factors greenhouse gas company reporting edition gsk restating scope emissions electricity based updated iea emission factors published gsk report marketbased scope emissions facilities evidence utility provider low carbon energy generation certificates origin rec rego ppa hydroelectric local grid supply eg quebec region scope carbon emissions gsk report scope categories detailed greenhouse gas scope data across categories prepared gsk using protocol hybrid model combining primary activitybased data available economic data model quality assured carbon trust scope emissions business travel air based ticketing information directly fuel use scope emissions patient use metered dose inhalers based numbers inhalers leaving manufacturing sites distribution amount propellant inhaler gsk esg performance summary march environmental data terminology continued kpi definition method waste waste generated operational waste leaves gsk boundaries waste data based invoices waste transfer note data beneficial use waste defined waste sent recycling reuse incineration energy recovery nonbeneficial use waste defined waste disposed either incineration energy recovery sent landfill waste landfill waste landfill includes hazardous nonhazardous waste waste landfill data based invoices waste transfer note disposed landfill data cases local laws regulations require certain waste sent landfill types waste eg asbestos waste landfill best environmental option include wastes waste sent landfill data table also allow small number sites affected claim zero landfill status ozone depleting substances report ozone depleting potential total amount ozone depleting total amount ozone depleting substances based site contained equipment substances contained ancillary equipment kg cfc equivalents inventory data multiplied ozone depleting potential factors intergovernmental panel climate change estimate impact fugitive losses refrigerants excluding inventory small number sites gsk manage refrigeration equipment gsk reportable incident gsk reportable injury illness meets following criteria consistent global reporting gsk reportable injury illness meets listed criteria criteria different affected individual either gsk employee complementary worker national regulatory reporting requirements vary across direct gsk daily supervision world incident work related lost time incident one resulted either days away outcome involved least one following work job restriction employee unable perform one fatality routine activities lost restricted days counted day following incident loss consciousness hours worked calculated based number working days medical treatment beyond first aid year length average workday number employees significant occupational injury occupational illness diagnosed site provided gsk human resources employees include physician licensed health care professional full time employees directly supervised agency staff restricted dayschange job dutiesdays away work gsk restating incident data account small must new case number incidents occurred records complete table prepared last year incident rates calculated per hours worked gsk esg performance summary march list products list prequalified medicinal products vaccines part prequalification medicines programme pqp type form presentation date prequalification vaccines engerix hepatitis b liquid ready use vial dose thursday january engerix hepatitis b liquid ready use vial doses thursday january engerix hepatitis b liquid ready use vial doses thursday january priorix measles mumps rubella lyophilised active component reconstituted excipient friday march diluent use vial dose rotarix rotavirus liquid ready use plastic tube dose thursday march rotarix rotavirus liquid ready use applicator dose thursday march cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october synflorix pneumococcal conjugate liquid ready use vial dose friday october synflorix pneumococcal conjugate liquid ready use vial doses friday march poliorix polio vaccine inactivated ipv liquid ready use vial dose thursday august poliorix polio vaccine inactivated ipv liquid ready use vial dose thursday august polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may priorix measles mumps rubella lyophilised active component reconstituted excipient wednesday december diluent use vial doses havrix adult hepatitis human diploid cell inactivated adult liquid ready use vial dose friday july havrix junior hepatitis human diploid cell inactivated paediatric liquid ready use vial dose friday july boostrix diphtheriatetanuspertussis acellular liquid ready use vial dose tuesday july menveo meningococcal acyw conjugate vaccine lyophilised active component reconstituted wednesday july liquid active component use two vial set dose synflorix pneumococcal conjugate liquid ready use vial doses monday october rotarix rotavirus liquid ready use plastic tube dose thursday february gsk esg performance summary march list products list prequalified medicinal products vaccines part prequalification medicines programme pqp continued type applicant ref number date prequalification pharmaceuticals abacavir sulfate hiv viiv healthcare ha march abacavir sulfate hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha may zidovudine hiv viiv healthcare ha may lamivudinezidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march dolutegravir sodium hiv viiv healthcare ha october abacavir sulfatelamivudine hiv viiv healthcare ha june zanamivir influenza gsk september gsk esg performance summary march sasb index produced first sustainability accounting standards board sasb index illustrate reporting aligns biotechnology pharmaceutical industry guidelines continue align reporting sasb future reports data information reported via range sources including public policies annual report esg performance summary gskcom index signposts relevant source gsk esg performance summary march sasb index sasb indicator find information safety clinical trial participants hcbpa discussion world region management process ensuring quality patient safety clinical trials clinical trials policy hcbpa number fda sponsor inspections related clinical trial management pharmacovigilance resulted reported voluntary action indicated vai official action indicated oai hcbpa total amount monetary losses result legal proceedings associated clinical trials developing reported countries access medicines hcbpa description actions initiatives promote access health care products priority diseases p annual report priority countries defined access medicine index hcbpa list products list prequalified medicinal products part prequalification medicines p document programme pqp affordabilty pricing hcbpb number settlements abbreviated new drug application anda litigation involved payments andor reported provisions delay bringing authorized generic product market defined time period hcbpb percentage change average list price average net price across us product portfolio compared p document previous year hcbpb percentage change list price net price product largest increase compared p document previous year drug safety hcbpa list products listed food drug administrations fda medwatch safety alerts available via human medical products database fda adverse event reporting website hcbpa number fatalities associated products reported fda adverse event reporting system available via fda adverse event reporting website hcbpa number fda recalls issued total units recalled p document hcbpa total amount product accepted takeback reuse disposal reported hcbpa number fda enforcement actions taken response violations current good manufacturing practices p document cgmp type gsk esg performance summary march sustainability disclosure topics accounting metrics continued counterfeit drugs hcbpa description methods technologies used maintain traceability products throughout p annual report supply chain prevent counterfeiting falsified substandard healthcare products hcbpa discussion process alerting customers business partners potential known risks p annual report associated counterfeit products hcbpa number actions led raids seizure arrests andor filing criminal charges related reported counterfeit products ethical marketing hcbpa total amount monetary losses result legal proceedings associated false marketing claims reported hcbpa description code ethics governing promotion offlabel use products arketing practices scientific engagement employee recruitment development retention hcbpa discussion talent recruitment retention efforts scientists research development personnel p annual report hcbpa voluntary involuntary turnover rate executivessenior managers b midlevel report turnover gender managers c professionals others p report supply chain management hcbpa percentage entitys facilities tier suppliers facilities participating rx gsk member rx also international pharmaceutical supply chain consortium audit program equivalent thirdparty audit conducts audits third parties programs integrity supply chain ingredients p business ethics hcbpa total amount monetary losses result legal proceedings associated corruption bribery reported hcbpa description code ethics governing interactions health care professionals c ode practice promotion prescription medicines scientific engagement activity metrics hcbpa number patients treated p annual report patients reached access strategies hcbpb number drugs portfolio research development phases p annual report pipeline see online products gsk esg performance summary march united nations statement support ceo gsk remains committed upholding global compact ungcs ten principles human rights environment anticorruption aim embedding policies standards across business gsk signatory un global compact ungc remaining true values compact challenges business operate according purpose help people ten principles covering bribery corruption feel better live longer human rights labour environment following emma walmsley index structured according criterion chief executive officer march advanced level communication progress cop compiled annual report gskcom website gsk esg performance summary march united nations global compact communication progress annual report find data online implementing principles strategies mainstreaming place responsibility execution sustainability strategy relevant corporate functions governance structure corporate functions procurement government affairs human resources legal etc ensuring function conflicts business units companys sustainability commitments objectives align strategies goals incentive structures business units subsidiaries longterm priorities p corporate sustainability strategy apply three businesses assign responsibility corporate sustainability implementation individual governance structure group within business unit subsidiary describes value communicate policies expectations suppliers relevant business partners working third parties p chain implementation implement monitoring assurance mechanisms eg audits screenings compliance working third parties p within companys sphere influence undertake awarenessraising training types capacity building suppliers working third parties p business partners carbon p robust human rights management policies procedures robust commitments commitment comply applicable laws respect internationally recognised human rights gsk human rights statement strategies policies wherever company operates area human rights integrated standalone statement policy expressing commitment respect support gsk human rights statement human rights approved senior level company statement policy publicly available communicated internally externally personnel gsk human rights statement business partners relevant parties describes effective ongoing due diligence process includes assessment actual potential human rights human rights p management systems impacts integrate human allocation responsibilities accountability addressing human rights impacts human rights p rights principles describes effective relevant policies procedures activities company plans undertake fulfil human rights p monitoring evaluation criterion including goals timelines metrics responsible staff gsk human rights statement mechanisms human rights integration system monitor effectiveness human rights policies implementation quantitative human rights p qualitative metrics including supply chain gsk human rights statement gsk esg performance summary march united nations global compact communication progress continued robust labour management policies procedures continued describes robust reference principles relevant international labour standards gsk human rights statement commitments ilo conventions normative international instruments company policies strategies policies inclusion reference principles contained relevant international labour standards human rights p area labour contracts suppliers relevant business partners describes effective risk impact assessments area labour working third parties p management systems grievance mechanisms communication channels procedures eg whistleblower ethics values p integrate labour mechanisms available workers report concerns make suggestions seek advice practices designed operated agreement representative organisation workers describes effective audits steps monitor improve working conditions companies supply chain working third parties p monitoring evaluation line principles international labour standards mechanisms labour process positively engage suppliers address challenges schemes improve working third parties p principles integration workplace practices robust environmental management policies procedures describes robust reflection relevance environmental stewardship company environment p commitments strategies written company policy environmental stewardship climate change policies area gsks operations environmental stewardship inclusion minimum environmental standards contracts suppliers relevant working third parties p business partners carbon p specific commitments goals specified years environment p describes effective environmental risk impact assessments climaterelated financial p management systems disclosure integrate water stewardship policy environmental principles allocation responsibilities accountability within organisation governance structure describes effective system track measure performance based standardised performance metrics environment p monitoring evaluation mechanisms audits steps monitor improve environmental performance companies working third parties p environmental supply chain stewardship gsk esg performance summary march united nations global compact communication progress continued robust anticorruption management policies procedures describes robust publicly stated formal policy zerotolerance corruption antibribery corruption commitments strategies policy policies area policy anticorruption regarding business partners antibribery corruption anticorruption policy third party guidelines describes effective support organisations leadership anticorruption ethics values p management systems internal checks balances ensure consistency anticorruption commitment ethics values p integrate anti corruption principle management responsibility accountability implementation anticorruption commitment ethics values p policy communications whistle blowing channels followup mechanisms reporting concerns ethics values p seeking advice speakup integrity line describes effective leadership review monitoring improvement results ethics values p monitoring evaluation mechanisms integration anti corruption taking action support global goals describes core business align core business strategy one relevant un goalsissues sdg factsheet contributions un goals issues develop relevant products services design business models contribute un goalsissues science technology p affordability availability p describes strategic pursue social investments philanthropic contributions tie core competencies science technology p social investments operating context company integrated part sustainability strategy affordability availability p philanthropy describes advocacy publicly advocate importance action relation one un goalsissues sdg factsheet public policy commit company leaders participate key summits conferences important public policy sdg factsheet engagement interactions relation one un goalsissues gsk esg performance summary march united nations global compact communication progress continued taking action support global goals continued describes partnerships develop implement partnership projects public private organisations core business product reach healthcare p collective action social investments andor advocacy access join industry peers un entities andor stakeholders initiatives contributing solving common product reach healthcare p challenges dilemmas global andor local levels emphasis initiatives extending access companys positive impact value chain corporate sustainability governance leadership describes ceo ceo publicly delivers explicit statements demonstrates personal leadership sustainability ungc cop ceo statement commitment commitment un global compact leadership ceo promotes initiatives enhance sustainability companys sector leads development ceos statement p industry standards describes board adoption board directors equivalent assumes responsibility oversight longterm corporate cr committee report p oversight sustainability strategy performance ceos statement board establishes permissible committee assigns individual board member cr committee report p responsibility corporate sustainability board committee permissible approves formal reporting corporate sustainability cr committee report p communication progress governance describes stakeholder publicly recognises responsibility companys impacts internal external stakeholders stakeholder engagement p engagement define sustainability strategies goals policies consultation key stakeholders stakeholder engagement p establish channels engage employees stakeholders hear ideas address ethics values p concerns protect whistle blowers speak integrity gsk esg performance summary march global reporting initiative guidelines base report gri guidelines produced gri index show elements gri standards covered reporting help comparison company reports gsk esg performance summary march global reporting initiative guidelines gri standard number description number responselink response general disclosures name organization glaxosmithkline plc activities brands products services httpwwwannualreportgskcom location headquarters brentford middlesex tw gs uk location operations countries ownership legal form httpwwwannualreportgskcom markets served httpwwwannualreportgskcom scale organisation httpwwwannualreportgskcom information employees workers httpwwwannualreportgskcom supply chain httpwwwannualreportgskcom significant changes organisation supply chain httpwwwannualreportgskcom precautionary principle approach httpwwwannualreportgskcom externally developed economic environmental social httpwwwannualreportgskcom charters principles initiatives organization subscribes endorses membership associations httpswwwgskcomengbresponsibilityresponsibilityreportsdata patientgroupfunding httpswwwgskcomengbresponsibilityresponsibilityreportsdata tradeassociationmemberships statement senior decisionmaker httpwwwannualreportgskcom values principlesstandards norms behaviour httpwwwannualreportgskcom governance structure organization including committees httpswwwgskcomengbresponsibility highest governance body responsible decisionmaking economic environmental social topics list stakeholder groups httpwwwannualreportgskcom identifying selecting stakeholders httpsgskcommediamaterialityassessmentpdf approach stakeholder engagement httpwwwannualreportgskcom key topics concerns raised httpsgskcommediamaterialityassessmentpdf gsk esg performance summary march global reporting initiative guidelines continued gri standard number description number responselink response changes reporting significant changes reporting period jandec date recent report reporting cycle annual contact point questions regarding report csrcontactgsk com claims reporting accordance gri standards httpswwwgskcomengbresponsibilityresponsibilityreportsdata reportingarchiveandresources gri content index external assurance document specific standard disclosures economic economic performance httpsgskcommediamaterialityassessmentpdf generic disclosures management approach direct economic value generated distributed httpwwwannualreportgskcom indirect economic impacts httpsgskcommediamaterialityassessmentpdf generic disclosures management approach significant indirect economic impacts including extent httpwwwannualreportgskcom impacts anticorruption httpsgskcommediamaterialityassessmentpdf generic disclosures management approach communications training anticorruption httpwwwannualreportgskcom approach tax httpswwwgskcommediataxstrategypdf tax governance control risk management httpswwwgskcommediataxstrategypdf gsk esg performance summary march global reporting initiative guidelines continued gri standard number description number responselink response social occupational health safety httpwwwannualreportgskcom generic disclosures management approach rates injury occupational diseases lost days absenteeism document work related fatalities training education httpwwwannualreportgskcom generic disclosures management approach employees receiving regular performance career httpwwwannualreportgskcom development reviews diversity httpwwwannualreportgskcom generic disclosures management approach diversity governance bodies employees httpwwwannualreportgskcom society marketing labelling httpsgskcommediamaterialityassessmentpdf generic disclosures management approach incidents noncompliance concerning product service httpswwwgskcomengbresponsibilityoperatingresponsibly information labelling human rights httpwwwannualreportgskcom generic disclosures management approach environment energy consumption within organization document reduction energy consumption httpwwwannualreportgskcom document reductions energy requirements products services httpwwwannualreportgskcom water httpsgskcommediamaterialityassessmentpdf generic disclosure management approach water withdrawal document water discharge document gsk esg performance summary march gri standard number description number responselink response climate change httpwwwannualreportgskcom generic disclosure management approach direct scope ghg emissions document energy indirect scope ghg emissions document indirect scope ghg emissions httpwwwannualreportgskcom document ghg emissions intensity httpwwwannualreportgskcom emissions ozonedepleting substances ods document waste packaging httpsgskcommediamaterialityassessmentpdf generic disclosure management approach water discharge quality destination document waste type disposal method document noncompliance environmental laws regulations document inclusion standard necessitated gsk publishing breakdown scope ghg emissions done esg performance summary gsk esg performance summary march gsk esg performance summary march gsk esg performance summary march public policies available online please see public policy positions gskcom provide information number number issues including topics including antimicrobial resistance materiality assessment care welfare treatment animals human rights clinical trials developing world sustainable development goals cloning stem cell technologies political advocacy code conduct patient group funding deforestation free sourcing trade association memberships impact climate change health charitable grant contributions genetically modified microorganisms environment criteria working public policy groups health safety ehs modern slavery act statement marketing practices scientific engagement preparing future disease threats nanotechnology ozone depletion metereddose inhalers asthma pharmaceuticals environment pie pharmacovigilance tax strategy working third parties gsk esg performance summary march cautionary statement document may contain forwardlooking statements forward authority group undertakes obligation update forward looking statements give groups current expectations forecasts looking statements whether result new information future future events investor identify statements fact events otherwise investors however consult additional relate strictly historical current facts use disclosures group may make documents words anticipate estimate expect intend project publishes andor files us securities exchange plan believe target words terms similar meaning commission sec investors wherever located take note connection discussion future operating financial disclosures accordingly assurance given performance particular include statements relating particular expectation met investors cautioned future actions prospective products product approvals future place undue reliance forwardlooking statements forward performance results current anticipated products sales looking statements subject assumptions inherent risks efforts expenses outcome contingencies legal uncertainties many relate factors beyond proceedings dividend payments financial results groups control precise estimate group cautions investors accordance legal regulatory obligations including number important factors including market abuse regulations uk listing rules disclosure presentation could cause actual results differ materially guidance transparency rules financial conduct expressed implied forwardlooking statement gsk esg performance summary march